Emergent Clinical Consulting, LLC Report issue

For profit Phase 1

Organization Overview

First Clinical Trial
2020
NCT04483297
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Emergent Clinical Consulting, LLC

Active Ingredients

Drugs in Phase 1 Trials (1)

ak1320 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Constriction, Pathologic (Phase 1)

Spinal Stenosis (Phase 1)

Spondylolisthesis (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1